Physicians' Academy for Cardiovascular Education

Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?

Listen to the podcast
10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD - Johannesburg, South Africa

Video navigation menu

  • LDLR dependent pharmacotherapy for HoFH 02:14
  • LDLR independent therapies: Lomitapide 04:36
  • LDLR independent therapies: ANGPTL3 inhibition 05:14
  • Treatment algorithm for HoFH 07:28


Show transcript

Educational information

This presentation by Prof. Raal is the second part of a series titled "HoFH: The need to treat - creating awareness, understanding and insights".


Prof. Frederick Raal, MD, PhD is head of the Division of Endocrinology & Metabolism and director of the Carohydrate and Lipid Metabolism Research Unit at the University of Witwatersrand, Johannesburg, South Africa.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from Ultragenyx.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: